Replies to post #692900 on NorthWest Biotherapeutics Inc (NWBO)

[underpar71]

We are on the OTC. We have had a year and a half of application prep and six more months of waiting for a decision from MHRA. Why have we not formulated and executed a plan to get on a real exchange? ALL positive news will be dulled due to the ability to manipulate even more on the OTC.

[manibiotech]

Agree
Unless they announce some plan to monetize ( besides usual selling share like candy a dime ) , any spike will be temporary I think .
Unless they announce some kind of partnership , JV , BO , large upfront capital from BP , and plan to start uplisting process , we will still be talking about how corrupt MMs are , how corrupt BP is and yada, yada

[kfa670]

As long as management has NOT arranged large sums of non dilutive cash or dilutive but against much higher SP we will not appreciate that much after UK approval. I hate to tell you this.

Unfortunately I believe you are right. Now, I do think it's likely that this sees an MHRA decision before the ASM. And no I don't mean the end of June. Management "plans" to have their meeting before the end of June. That means absolutely nothing in my experience. So I would wager June is them hoping optimistically they have decision (positive) in hand by then.

So if we have positive decision, then ASM, then some actual GUIDANCE as to what the plan for the future to get off the "mickey mouse" exchange.... Phew... That's a lot of hoping but here's to hoping it happens

[Investor082]

“As long as management has NOT arranged large sums of non dilutive cash or dilutive but against much higher SP we will not appreciate that much after UK approval. I hate to tell you this.”

-Agreed. Also, any spike we get at UK approval will give back most of its gain if large non dilutive cash is not accompanied in parallel. Plus no hiring on the commercial front will make matters worse, if there is no partner to take on GBM sales. Again, the usual pumpers will play the victim card, but the management must be blamed. They have had years to plan for this!

[skitahoe]

I believe that if you look at other companies post approval you'll find they have market caps of a couple billion dollars, or more. Our market cap is just over half a billion. A two billion market cap will put us close to $2 a share.

Frankly I believe our potential is far greater than most biotech's with their initial approvals, certainly some of their products have blockbuster potential, but our vaccine could go well over the potential of most of the others. As our story becomes better know, I believe our market cap could certainly reach $5 billion or more on UK approval alone.

It's hard to say if UK approval alone will build the share price to the point where we can move to the Nasdaq or NYSE, more than $5 billion in market cap is needed for that, but add some news on the EDEN or filing with other regulators for approval and that should get us there. I believe we'll see this by the end of this year.

All the above is assuming that we don't get an emotional reaction to the approval. If approval gains major media attention, headlines saying our vaccine is a new paradigm in the treatment of cancer, IE investors want in regardless of the share price, no telling how high we might go. Certainly we'll retrench, but if our high is $10 or more, we'll retrence 30 to 50% of that high, so $5 or more, that will be sufficient to get on whatever exchange LP wants. Frankly I don't know that emotion won't take us much higher than $10, if it does I do intend to put trailing stops on at least some of my shares, and certainly all that are in Roth's. We've all seen $1 stocks go to $100, then fall back to practically where they started, I don't believe that will happen, but with the right media attention a high at $20 or more is not impossible. If such a thing occurred, I'm not sure it wouldn't be sustained by a partnership with a BP.

Gary